Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group study (JCOG0805)

Japanese Journal of Clinical Oncology

Volumn 40, Issue 12, 2010, Pages 1189-1191

  Takashima, Atsuo ^a   Morizane, Chigusa ^b   Ishii, Hiroshi ^c   Nakamura, Kenichi ^a   Fukuda, Haruhiko ^a   Okusaka, Takuji ^b   Furuse, Junji ^d  

^a NATIONAL CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c Cancer Institute Hospital   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gemcitabine; Iliary tract cancer; Randomized Phase II selection design trial; S 1

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILIARY TRACT CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; JAPAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; MALE; MIDDLE AGED; OXONIC ACID; PATIENT SELECTION; SAMPLE SIZE; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 78649585699     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq110     Document Type: Article

References (9)

1. Hirohashi S. Cancer Statistics in Japan 2009. 2009.
2. Yamaoka Y, Ukai I, Arii S, Ichida T, Okita K, Omata M, et al. The 16th national follow-up survey report on primary hepatic cancer (2000-2001). Kanzou 2005;46:234-54 (in Japanese).
3. Furuse J, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008;15:55-62.
4. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008;13:415-23.
5. Valle J, Wasan H, Palmer HD, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
6. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 2008;62:849-55.
7. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006;57:647-53.
8. Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, et al. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65:1101-7.
9. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-81.